(Q44679844)

5 December 2017

title

Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? (English)

1 reference

5 December 2017

Costica Aloman

1

1 reference

5 December 2017

Jack R Wands

series ordinal

2

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

5 December 2017

1 reference

5 December 2017

volume

38

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

1584-1587

1 reference

A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Burden of liver disease in the United States: summary of a workshop

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Combination chemotherapy for hepatitis B virus: the final solution?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510380633

7 January 2021

Identifiers

DOI

10.1002/HEP.510380633

0 references

1 reference